Get the Stockscreener App
6.15
2.16%
0.13
Aura Biosciences Inc stock is traded at $6.15, with a volume of 963.07K.
It is up +2.16% in the last 24 hours and down -22.15% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.02
Open:
$6.01
24h Volume:
963.07K
Relative Volume:
1.31
Market Cap:
$637.78M
Revenue:
-
Net Income/Loss:
$-112.39M
P/E Ratio:
-3.4878
EPS:
-1.7633
Net Cash Flow:
$-91.64M
1W Performance:
-6.68%
1M Performance:
-22.15%
6M Performance:
-2.54%
1Y Performance:
-0.32%
1-Day Range:
$5.95
$6.25
1-Week Range:
$5.95
$6.73
52-Week Range:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.15 | 637.78M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage - Investing.com
AURA Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Biotech Misses EPS EstimateLow Growth Earnings - dars.gov.et
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences to Participate in Upcoming Investor Conference - GlobeNewswire
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16 - Stock Titan
Aura Biosciences (AURA) boosts finance chief with new stock grants - Stock Titan
COO at Aura Biosciences (AURA) lands new option and RSU package - Stock Titan
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives - quiverquant.com
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura (AURA) Results at a Glance: EPS Misses Its Estimate under the Current Snapshot; Market Move: Shares Move 0.39% Higher on the DayGuidance Revision Trend - vinanet.vn
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Long Focus Capital Management Expands Stake in Aura Biosciences Inc (AURA) With Strategic Add - GuruFocus
Aura (AURA) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison for the Current Session; Price Move - vinanet.vn
Aura Biosciences Extends Bel-sar Data With Long-Term Follow-Up Study - TipRanks
AURA Q1 2026 Earnings: Wider Net Loss of $0.50 Per Share Weighs on SharesEstimate Revision Count - vinanet.vn
AURA Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Commercial Pipeline CostsRevenue Warning Signal - vinanet.vn
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - MarketBeat
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - tradingview.com
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount - stocktitan.net
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - TipRanks
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary - TradingView
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
AURA: Q2 net loss widened to $45.6M; $280.8M raised, restructuring shifts focus to ocular oncology - TradingView
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss - Quiver Quantitative
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029 - TradingView
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks |
Jun 16 '26 |
Sale |
6.42 |
12,824 |
82,330 |
265,354 |
| Matrix Capital Management Comp | 10% Owner |
May 07 '26 |
Sale |
5.64 |
6,922,870 |
39,044,987 |
0 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):